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GDI1 knockout miceObjectives: GDI1 gene encodes forαGDI, a protein controlling the cycling of small GTPases, reputed to orchestrate
vesicle trafficking. Mutations in human GDI1 are responsible for intellectual disability (ID). In mice with ablated
Gdi1, a model of ID, impaired working and associative short-term memory was recorded. This cognitive pheno-
type worsens if the deletion of αGDI expression is restricted to neurons. However, whether astrocytes, key ho-
meostasis providing neuroglial cells, supporting neurons via aerobic glycolysis, contribute to this cognitive
impairment is unclear.
Methods: We carried out proteomic analysis and monitored [18F]-fluoro-2-deoxy-D-glucose uptake into brain
slices of Gdi1 knockout and wild type control mice. D-Glucose utilization at single astrocyte level was measured
by the Förster Resonance Energy Transfer (FRET)-based measurements of cytosolic cyclic AMP, D-glucose and
L-lactate, evoked by agonists selective for noradrenaline and L-lactate receptors. To test the role of astrocyte-
resident processes in disease phenotype, we generated an inducible Gdi1 knockout mouse carrying the Gdi1 de-
letion only in adult astrocytes and conducted behavioural tests.
Results: Proteomic analysis revealed significant changes in astrocyte-resident glycolytic enzymes. Imaging [18F]-
fluoro-2-deoxy-D-glucose revealed an increased D-glucose uptake in Gdi1 knockout tissue versus wild type con-
trol mice, consistent with the facilitated D-glucose uptake determined by FRET measurements. In mice with Gdi1
deletion restricted to astrocytes, a selective and significant impairment inworkingmemorywas recorded, which
was rescued by inhibiting glycolysis by 2-deoxy-D-glucose injection.e; CNS, central nervous system; CFP, cyan fluorescent protein; CS, conditional stimulus, tone; CTX, context memory; [18F]-FDG,
nergy Transfer; GDI1, guanosine dissociation inhibitor 1 gene; GlastGdi1flox/Y, GLAST:CreERT2+/Gdi1lox/Y inducible astrocyte-
X/Y) carrying the GLAST:CreERT2 transgene; Gdi1 KO, full knockout of Gdi1; Gdi1WT, wild type;αGDI,α guanosine dissociation
acidic protein; GLUT1, D-glucose transporter; 2-DG, 2-deoxy-D-glucose; GPR81, G-protein receptor 81; GPCR, G-protein coupled
renaline; 3-Cl-5-OH-BA, 3-chloro-5-hydroxybenzoic acid; PKA, protein kinase A; PSD, postsynaptic density; SEM, standard error
currents; SV, synaptic vesicle; XLID, X-linked intellectual disability; YFP, yellow fluorescent protein.
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P. D'Adamo, A. Horvat, A. Gurgone et al. Metabolism Clinical and Experimental 116 (2021) 154463Conclusions: These results reveal a new astrocyte-basedmechanism in neurodevelopmental disorders and open a
novel therapeutic opportunity of targeting aerobic glycolysis, advocating a change in clinical practice.
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Human intellectual disability is a common human
neurodevelopmental disorder with an early onset in postnatal life, af-
fecting approximately 1%–3% of the population [1]. In recent years,
>100 different X-linked genes encoding for proteinswith a large variety
of functions have been identified [2–4]. Thus, the final phenotypic out-
come of intellectual disability appears to reflect many different types
of abnormal cellular processes leading to neuronal dysfunction [2].
Mutations in the human GDI1 gene cause X-linked intellectual
disability (XLID) clinically characterized by “pure” cognitive deficit
without additional clinical features [5]. This gene encodes for αGDI,
a protein that controls the cycling of RAB GTPases, which in turn or-
chestrate specific vesicular trafficking steps by switching from an ac-
tive GTP-bound conformation to an inactive GDP-bound
conformation [6]. The role of αGDI is to actively retrieve GDP-
bound RAB GTPases from the membrane to form a soluble cytosolic
complex of inactive RAB proteins.
In line with this, it has been demonstrated that full ablation of Gdi1
(Gdi1 knockout [KO]) impaired hippocampal-dependent forms of
short-term memory; namely, working and associative fear-related
memory formation [7]. This cognitive deficit has also been observed in
a conditional Gdi1 KO (CaMKII-Cre+-Gdi1flox/Y) murine model, where
gene inactivation occurred solely in post-mitotic neurons of the adult
anterior forebrain. Moreover, electrophysiological comparison at
cortico-amygdala synaptic connections between theGdi1KO and condi-
tional Gdi1 mice revealed a stronger pre-synaptic phenotype in condi-
tional Gdi1 mice, confirming the pivotal role of αGDI in hippocampal,
cortical and amygdala synapses in the process of memory formation
[8]. Although XLID-related cellular defects arise from impaired neuronal
processes, it is also possible that altered function of astrocytes contrib-
utes to the behavioural phenotype in Gdi1 KO animals, as astroglia are
the key cell type providing homeostasis and represent a central element
in neuropathology [9,10].
Here, we investigated whether astrocytes, bearing important patho-
logical potential, contribute to the phenotype of XLID [10,11]. The re-
sults reveal that by limiting Gdi1 deletion to astrocytes in an inducible
conditionalGdi1KOmouse (GlastGdi1flox/Y), the behavioural deficit is re-
stricted to alteration in working memory. This cognitive deficit is asso-
ciated with impaired astrocytic aerobic glycolysis, characterized by
facilitated D-glucose utilization controlled by receptor-mediated cAMP
signalling. Moreover, inhibition of glycolysis by the injection of 2-
deoxy-D-glucose (2-DG) [12] improves the Gdi1 KO mice behavioural
phenotype, revealing a new astrocyte-based therapeutic targeting op-
portunity for this form of XLID.
2. Methods and materials
Unless noted otherwise, all chemicals were of the highest quality
available and purchased from Sigma-Aldrich (Merck KGaA, Darmstadt,
Germany).
2.1. Cell culture and transfection
Primary astrocytes were isolated from cortices of P2 Gdi1 WT and
Gdi1 KO mice as described [13] and grown as in Giannandrea et al.
[14]. Transfection with plasmids carrying FRET-based nanosensors
was performed with FuGENE 6 transfection reagent according to the
manufacturer's instructions (Promega, Madison, WI, USA).2
The experimental protocol was approved by The Administration of
the Republic of Slovenia for Food Safety, Veterinary and Plant Protection
(Republic of Slovenia, Ministry of Agriculture, Forestry and Food,
Dunajska cesta 22, 1000 Ljubljana), Document No. U34401-47/2014/7,
signed by Barbara Tomše, DVM.
2.2. SILAC proteomics
Primary astrocytic cells were labelled by culturing them for 14 days
in the appropriate medium containing the light (for Gdi1WT labelling:
L) and heavy (for Gdi1 KO labelling: H) versions of arginine and lysine.
Once complete incorporation had occurred, cells were harvested,
counted and mixed 1:1 (<3million of cells per sample) and the subcel-
lular compartments (cytosol, membrane, nucleus and cytoskeleton)
were fractionated using a Qproteome Cell Compartment kit (QIAGEN,
Dusseldorf, Germany), following the manufacturer's instructions. Sam-
pleswere precipitatedwith acetone to get rid of salts and contaminants,
re-suspended in RIPA buffer (500mMTris-HCl [pH 7.4], 200mMNaCl, 1
mM EDTA, 1% Triton X-100, 1% NP-40, protease inhibitor cocktail), and
then proteins were resolved on a pre-cast SDS-PAGE gel, 4%–12%
(Invitrogen, Carlsbad, CA, USA) and stained using colloidal Coomassie
(Bio-Rad, Hercules, CA, USA). Single lanes were then cut into bands,
each band was chopped into small pieces, reduced with 1,4-dithiothre-
itol (DTT), alkylatedwith iodoacetamide, digestedwith trypsin [15] and
desalted using StageTip (Proxeon Biosystems, Odense, Denmark).
Resulting peptides were resolved onto a 15-cm-long C18 column. A
95-min long gradient of eluents A (pure water with 2% v/v acetonitrile
[ACN], 0.5% v/v acetic acid) and B (ACN with 2% v/v pure water with
0.5% v/v acetic acid) was used to achieve separation, from 7% B (at 0
min, 0.2 μL/min flow rate) to 70% B (at 95 min, 0.2 μL/min flow rate).
The liquid chromatography system was connected to an LTQ
Orbitrap mass spectrometer (Thermo Scientific, Bremen, Germany)
equipped with a nanoelectrospray ion source (Proxeon Biosystems,
Odense, Denmark). The acquisition mass range for each sample was
from m/z 350 to 1700 Da, and the analyses were done in duplicate.
Full scans were acquired at high resolution (R = 60,000 at 400 m/
z), and the automatic gain control (AGC) target was set to 1 × 106
at a maximum injection time of 500 ms. The 15 most intense peaks
were automatically selected, fragmented by collision-induced disso-
ciation set at 37, and acquired in the linear ion trap at low resolution,
AGC target 1 × 104, and 3 microscans of 150 ms each. Ions acquired
twice were dynamically excluded for further selection and fragmen-
tation for 90 s. Spectra were loaded intoMaxQuant software (version
1.1.1.25) [16] and searched against the mouse International Protein
Index database (release 20100819) using the Andromeda search en-
gine [17]. Search parameters were as follows: trypsin strict specific-
ity for cleavage, carbamidomethylation as fixed modification,
methionine oxidation, and protein N-terminal acetylation as variable
modifications, 2 missed cleavages allowed, 10 ppm tolerance for the
precursor, and 0.5 Da tolerance for the fragment ions. To be consid-
ered as identified, proteins had to pass the following criteria: mini-
mum peptide length of 6, at least 1 assigned peptide and 1 unique
peptide. The false discovery rate for both peptides and proteins
was set at 0.01. Keratins and proteins derived from foetal calf
serum have been removed from further analysis. SILAC quantifica-
tion was done according to the MaxQuant algorithm on razor and
unique peptides, with at least 1 ratio count. Statistical analysis was
performed using Perseus tools available in the MaxQuant
environment.
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[18F]-FDGwas prepared for clinical use as indicated in the European
Pharmacopeia, VIII edition. Autoradiography experiments were per-
formed on 3-months-old mice sacrificed 1 h after tail vein injection of
135.3 ± 19.7 μCi [18F]-FDG. Brain was rapidly removed and placed
into a specific brainmatrix (Stoelting, Wood Dale, IL, USA); 2-mm slices
were cut with stainless steel blades and exposed for 1 h to a phosphor
screen. After that, images were acquired with PhosphorImager
(CycloneScan, Perkin Elmer, Waltham, MA, USA) and analysed using
Optiquant software. [18F] radioactivity in mouse brains was calculated
as a percentage of the injected dose (ID) per brain area analysed (%ID/
mm2). Two types of analysis were performed using the region of inter-
est (ROI): for the first, each slice was surrounded manually and
contained radioactivity reported as the sum of all slices (% of total
brain); for the second, different brain areas (cortex, striatum, hippo-
campus, thalamus and cerebellum) were surrounded manually to ob-
tain %ID/mm2.
2.4. Glucose measurements
Blood glucose was determined using the Roche ACCU−CHEK® Ac-
tive meter. Serum levels of insulin and C-peptide were detected using
multiplex bead-based assays based on x Multi-Analyte Profile technol-
ogy (MILLIPLEX MAP Mouse Metabolic Hormone Magnetic Bead
panel). Assay was performed following the manufacturer's protocols
and run on MAGPIX (Biorad) with Bio-Plex manager software v6.1
(Bio-Rad). Oral glucose tolerance test (OGTT) was performed on mice
that were fasted at least for 12 h. Animals were orally administered,
by oral gavage, with glucose solution (1 mg/g BW). Blood glucose was
determined from the tail vein at seven-time points: 0 (before glucose
load), 10 (10min after glucose load), 20, 30, 60, 90 and 120min. Insulin
tolerance test (ITT) was performed as follows: the mice were fasted for
4 h and intraperitoneally injected with 0,75 U/kg BW of insulin
(Actrapid, Novo Nordisk). Blood glucose was determined from the tail
vein at eight-time points: 0 (before insulin load), 15 (15 min after insu-
lin load), 30, 45, 60, 75, 90 and 120 min.
2.5. Immunohistochemistry
Harvested tissues were fixed in 10% buffered formalin, embedded in
paraffin, cut and stained with hematoxylin and eosin for morphological
analysis. For immunohistochemical analysis, 3 μm sections were incu-
bated with polyclonal anti-glucose transporter GLUT1 antibody
(1:200; Abcam, Cambridge, UK, ab15309) or anti-GFAP (1:500; Dako,
Glostrup, Denmark, Z0334) after antigen retrieval with Tris-EDTA (pH
9) in a warm bath, and the immunoreaction was revealed with a
rabbit-on-rodent HRP-polymer (Biocare Medical, Pacheco, CA, USA),
using 3,3-diaminobenzidine as chromogen and counterstaining with
hematoxylin.
2.6. Immunostainings, in situ hybridization and image analysis
Immunofluorescence staining on primary cultured astrocytes was
performed as described [7]. The following primary antibodies were
used: rabbit polyclonal anti-MCT1 (1:50; Abcam, Cambridge, UK,
ab93048), rabbit polyclonal anti-MCT4 (1:50; Santa Cruz Biotechnol-
ogy, Dallas, TX, USA, SC-50329), rabbit monoclonal anti-α1A-AR
(1:1000; Abcam, Cambridge, UK, ab137123), rabbit polyclonal anti-
α2A-AR (1:100; Biorbyt, Cambridge, UK, orb10054), rabbit
polyclonal anti β1-AR (1:200; Abcam, Cambridge, UK, ab85037), rabbit
polyclonal β2-AR (1:100; Biorbyt, Cambridge, UK, orb10056) or rabbit
polyclonal β3-AR (1:100; Biorbyt, Cambridge, UK, orb10057). Images
were acquired using an inverted Zeiss LSM510 META confocal micro-
scope with an oil immersion plan apochromatic objective (63×, 1.4
NA; Carl Zeiss, Jena, Germany) and 488-nm Ar-ion laser excitation.3
Emission spectra were acquiredwith a 505–530-nmbandpass emission
filter or>505 nm longpass emissionfilter. The number ofMCT1-,MCT4-
, α1A-AR-, α2A-AR-, β1-AR-, β2-AR- and β3-AR-positive green fluores-
cence pixels above the intensity threshold set at 20% and the number
of all pixels (total cell pixels) were determined in individual cells
using the ROI tool in the LSM 510 META software. The percentage of
positive pixels (green labelled) versus total cell pixel area was calcu-
lated in Gdi1WT and Gdi1 KO astrocytes using Excel (Microsoft, Seattle,
WA, USA). In the case of ARs, the values were normalized to mean
values of WT astrocytes for each receptor separately.
Murine brain slices were prepared and immunostained as described
by Bianchi et al. [8]. Monoclonal anti-GFAP antibody was used (1:100;
Sigma-Aldrich, St. Louis, MO, USA, G-3893).When immunofluorescence
was coupled to in situ hybridization, this was performed as in D'Adamo
et al. [7]. Images were captured using a Zeiss AxioImager M2m (Carl
Zeiss, Jena, Germany) equipped with a 10× objective. GFAP density
was calculated using the Gran Filter plugin for ImageJ (NIH, Bethesda,
MD, USA) and normalized on the area being considered. Colocalization
between Gdi1 and GFAP was analysed using the Colocalization plugin
for ImageJ.2.7. Surface biotinylation
Biotinylation assays on cultured primary astrocytes were performed
as described in Diering et al. [18]. Then western blot (WB) experiments
were performed by loading protein extracts onto a 12% polyacrylamide
gel, then transferred to a nitrocellulose membrane using a TurboBlot
machine (Bio-Rad). Polyclonal anti-GLUT1 (WB 1:500; Abcam, Cam-
bridge, UK, ab15309), polyclonal anti-αGDI (WB 1:20,000; Invitrogen,
Carlsbad, California, USA, 71-0300) antibodies were used, and poly-
clonal anti-Calnexin (WB 1:10,000; Sigma, St. Louis, Missouri, USA, C-
4731)was employed to normalize the total amount of protein. Analyses
were done using ImageJ software.2.8. FRET measurements of cAMP-dependent PKA activity
Gdi1 WT and Gdi1 KO astrocytes expressing the FRET-based PKA
nanosensor AKAR2 [19] were examined 24–48 h after transfection
with a Plan NeoFluar 40×/1.3 oil differential interference contrast im-
mersion objective (Carl Zeiss) using a Zeiss LSM510 META confocal mi-
croscope (Carl Zeiss). Cells were excited at 458 nm, and images (512 ×
512)were acquired every 3.5 s using lambda stack acquisition. Emission
spectra were collected from the META detector in 8 channels (lambda
stack) ranging from 470 nm to 545 nm, each 10.7 nm wide. Two-
channel (cyan fluorescent protein [CFP] and yellow fluorescent protein
[YFP]) images were generated using the analytical software Extract
channels (Zeiss LSM510 META). Channels with emission spectra at
470 and 481 nmand emission spectra at 513, 524, and 534 nmwere ex-
tracted to the CFP and YFP channels, respectively. YFP and CFP fluores-
cence intensities were quantified within an ROI selected for individual
cells expressingAKAR2using the LSM510META software. In the graphs,
the FRET ratio signal was reported as the ratio of the YFP/CFP (AKAR2)
fluorescence signals after subtracting the background fluorescence
from the signals using Excel. The values of the FRET signals were nor-
malized to 1.0. An increase in the FRET signal reflects an increase in
cAMP-dependent PKA activity.
Initially, astrocytes were kept in an extracellular solution (10mM
HEPES/NaOH [pH 7.2], 10mM D-glucose, 131.8mM NaCl, 1.8mM
CaCl2, 2mM MgCl2, 5mM KCl, 0.5 mM NaH2PO4·H2O, and 5 mM
NaHCO3) and were then treated with various reagents following a
100-s baseline: 100 μM NA, 2 or 20 mM L-lactate or 0.5 mM 3Cl-5OH-
BA (Santa Cruz Biotechnology, Dallas, TX, USA). The osmolality of the
extracellular solution was ~300 mOsm, measured with a freezing
point osmometer (Osmomat 030, Gonotech, Berlin, Germany).
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Gdi1WT and Gdi1 KO astrocytes expressing the FRET-based glucose
nanosensor FLII12PGLU-700 μΔ6 (www.addgene.org) [20,21] or the
FRET-based lactate nanosensor Laconic [22] were examined 16–48 h
after transfection with a fluorescence microscope (Zeiss Axio Ob-
server.AI, Zeiss, Oberkochen, Germany), with a CCD camera and mono-
chromator Polychrome V (Till Photonics, Graefelfing, Germany) as a
monochromatic source of light with a wavelength 436 nm/10 nm.
Dual emission intensity ratios were recorded using an image splitter
(Optical Insights, Tucson, AZ, USA) and 2 emission filters; 465/30 nm
for ECFP or mTFP and 535/30 nm for EYFP or Venus. Images were ac-
quired at 10 s with an exposure time of 0.1 s. The background fluores-
cence was subtracted from individual EYFP or Venus and ECFP or
mTFP fluorescence signals. The FRET ratio signals, EYFP/ECFP
(FLII12PGLU-700μΔ6) and mTFP/Venus (Laconic), were obtained from
integration of the ratio signal over the entire cell using Life Acquisition
software (Till Photonics, Graefelfing, Germany). The values of the FRET
signals were normalized to 1.0. An increase in the FRET ratio signal re-
flects increases in the [glucose]i and [lactate]i.
Initially, cells were kept in extracellular solution (10mM HEPES/
NaOH [pH 7.2], 3mM D-glucose, 135.3mM NaCl, 1.8mM CaCl2, 2mM
MgCl2, 5mM KCl, 0.5 mM NaH2PO4·H2O, 5 mM NaHCO3), after which
they were treated with various reagents following a baseline: 200 μM
NA, 20 mM L-lactate or 6 mM CHC (Sigma-Aldrich), an MCT blocker.
In some of the experiments cells were pre-incubated in extracellular so-
lution without D-glucose, with 3 mM 2-DG, and with a mixture of 1.5
mMD-glucose and 1.5mM2-DG for 30min at 37 °C and then stimulated
with 200 μMNA in the incubating solutions. The solution with CHCwas
prepared by diluting CHC ethanol stock solution (130mM) in the extra-
cellular solution. The final concentration of ethanol was 4.6%, which did
not significantly influence the FRET signal.
Extracellular solution osmolality was ~300 mOsm/L, as measured
with an Osmomat 030 osmometer.
2.10. FRET signal analysis
Single exponential and double exponential increases to maximum
functions (F = F0 + c × (1 − exp(−t /τ)) or F = F0 + c1 × (1 − exp
(−t / τ1) + c2 × (1− exp(−t / τ2))), respectively) were fitted to the di-
agrams with FRET ratio signals using SigmaPlot. The time constants (τ)
and the FRET ratio signal amplitudes (c) were determined from the
fitted curves. F is the FRET ratio signal at time t, F0 is the baseline FRET
ratio signal, c is the FRET ratio signal amplitude of F − F0, c1 and c2 are
the fluorescence amplitudes of individual exponential components of
a double-exponential function and τ is the time constant of the individ-
ual exponential component.
2.11. Calcium measurements
Astrocyte-loaded coverslips were incubated for 30 min at room
temperature in culture medium supplemented with 5 μM Fluo-4 AM,
a cell-permeant fluorescent calcium indicator (Thermo Fisher Scientific,
Waltham, MA, USA). Then cells were washed with extracellular solu-
tion, incubated for a further 30 min to allow de-esterification of
acetoxymethyl ester and mounted into the chamber on a confocal mi-
croscope equipped with a Plan-Apochromat air objective 20×/NA 0.8.
Fluo-4 was excited by a 488-nm argon laser line and emission fluores-
cence was filtered with a 495–565 bandpass filter. Time-lapse images
were acquired every second for 5 min before and 10 min after the
bolus addition of the stimulus, which reached a final concentration of:
0.5 mM 3Cl-5-OH-BA (Santa Cruz Biotechnology, Dallas, TX, USA), 10
mM L-lactate and 100 μM ATP. Time-dependent changes in Fluo-4 fluo-
rescence indicating increases in [Ca2+]i were acquired by LSM780 soft-
ware (Zeiss) within manually outlined ROIs that encompassed
individual cells. The baseline fluorescence (F0) was determined at the4
beginning of each recording as the average intensity (in arbitrary
units) during the first 300 frames. Custom-written Matlab software
(MathWorks, Natick,MA,USA)wasused to obtain thepeak calciumam-
plitude (ΔF/F0) and the surface under the curve (corresponding to time-
integrated calcium amplitudes (ΔF/F0 × t)).
2.12. Generation of GLAST::CreERT2/Gdi1flox mice
Heterozygote Gdi1lox/X female mice [8] were crossed with transgenic
GLAST::CreERT2 male mice [23] (obtained from M. Götz, Munich,
Germany). Mice genotype was analysed by PCR analysis of DNA ex-
tracted from the tail using primers Lox1 (5′ GGA AGA CTT GGA AGC
TGA AAG CTT T 3′) and Lox2 (5′ CAT GAT GCC AGA CAG GAT GCA TTC
3′), GLAST F8 (5′ GAG GCA CTT GGC TAG GCT CTG AGG A 3′), GLAST
R3 (5′ GAG GAG ATC CTG ACC GAT CAG TTG G 3′) and GLAST CER1 (5′
GGT GTA CGG TCA GTA AAT TGG ACA T 3′) as previously described[8;
23]. All animals were maintained on a 12 h light/dark cycle at 22–25
°C. Food pellets and water were available ad libitum.
2.13. Tamoxifen administration
Tamoxifen (Tx, 20mg/mL solution) (Sigma, St. Louis, Missouri, USA,
T-5648) was dissolved in corn oil (Sigma, St. Louis, Missouri, USA, C-
8267) at 45 °C for 4 h. To optimize Cre activity induction in the adult
brain and obtain GlastGdi1flox/Y, thirty days old GlastGdi1lox/Y andWT an-
imals were injectedwith 100mg/kg Tx intraperitoneally twice a day for
5 days. NT GlastGdi1lox/Y and WT mice were injected with corn oil. Tx-
treated mice were analysed 1 month after the last Tx injection.
2.14. Electron microscopy
Three-month-old GlastGdi1flox/Y and WT littermate mice were per-
fused transcardially with 2% paraformaldehyde, 2.5% glutaraldehyde, 2
mM CaCl2 in 150mM cacodylate buffer (pH 7.4). After perfusion, brains
were removed from the skull and further fixed over night at 4 °C. A
McIlwain tissue chopper was used to obtain 200-mm-thick sagittal
slices, and small pieces of the CA1 region were cut with a razor blade.
Samples were then post-fixed according to the ROTO procedure (re-
duced osmium-thiocarbohydrazide-osmium) by sequentially incubat-
ing in 1% osmium tetroxide, 1.5% potassium ferrocyanide in 150mM
cacodylate buffer (pH 7.4) for 1 h on ice, 1% thiocarbohydrazide solution
in dH2O for 20 min and 2% osmium tetroxide in dH2O for 30 min. After
rinsing in dH2O, sampleswere stained en bloc with uranyl acetate over-
night and dehydrated in increasing concentrations of ethanol and pro-
pylene oxide, and finally embedded in Epon. Samples were cured at
60 °C in an oven for 48 h. Epon blocks were sectioned using a Leica
EM UC7 ultramicrotome (Leica Microsystems, Wetzlar, Germany). Hip-
pocampal CA1 samples were cut from the slide at Bregma – 2.20 mm
and – 2.40 mm rostrocaudally. Serial ultrathin sections (60 μm) were
collected on pioloform-coated single-slot copper grids and examined
with a CM100 electron microscope (Philips Electron Optics, Eindhoven,
the Netherlands) at 80 kV.
The selected section was oriented at 700× magnification to select 4
random fields at least 80 μm distant within the middle portion of CA1
stratum radiatum. Four to eight non-overlapping images at 3–5 μmdis-
tance were captured per random field at an initial 27,500× magnifica-
tion. In total, 25 images or an area of 380 μm2 were sampled for each
animal with a Bioscan Camera 792 (Gatan, Pleasanton, CA, USA) using
Digital Micrograph 2.5 software (NCMI, Houston, TX, USA). A synapse
was identified by the clustering of synaptic vesicles (SVs) and by the
presence of a postsynaptic density. Synaptic profiles touching the exclu-
sion lines were not counted. The lengths of active zones, the number of
SVs and the areas of the axonal terminals were measured by using
ImageJ software. The density of SVs per axon terminal area was ob-
tained by dividing the number of SVs by the cross-section area of the
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2.15. Behavioural tests
Animals were maintained on an inverted 12 h light/dark cycle at
22–24 °C. All behavioural procedures were approved by the Animal
Care of the San Raffaele Scientific Institute, and by the National Ministry
of Health (IACUC nos. 652 and 653). All the behavioural tests were
assessed on 3- to 4-month-old mice, comparing GlastGdi1flox/Y and
GlastGdi1X/Y littermates. We used GlastGdi1X/Y mice as controls to evalu-
ate the toxicity of the Tx injection and the Cre activitywithout loxP sites.
2.15.1. Novelty test
Frames of non-reflective aluminium (37-cmhigh)were used to par-
tition the open field into 4 square 50 × 50 cm arenas, allowing for con-
current observation of 4 animals. The novel object was a 50-mL Falcon
tube positioned vertically in the centre of the arena. Each animal was
observed for 30 min in the empty arena after 30 min pre-exposure the
day before. The novel object was then introduced and observation con-
tinued for another 30min. For the time-course analysis, the total obser-
vation time was portioned into 6 periods of 10 min.
2.15.2. Water maze
The standard hidden-platform version of the water maze was done
as previously described [24,25]. Briefly, the test included an acquisition
phase (18 trials, 6/day, inter-trial time 30–40 min) followed by a rever-
sal phase duringwhich theplatformwasmoved to the opposite position
(12 trials, 6/day). The trials were averaged in blocks of 2 trials for the
analysis.
2.15.3. Radial maze
The apparatus consisted of 8 arms (38-cm long, 7-cmwide) extend-
ing from an octagonal centre platform (diameter 18.5 cm) with 5-cm
transparent plastic walls. The distance from the platform centre to the
end of each arm was 47 cm. A cup with a food pellet was present at
the end of each arm. Food-deprived mice (maintained at 85% of their
free-feeding weight) were placed in the centre platform and allowed
to collect pellets placed at the end of each arm for 10 min. The animals
were adapted to themaze for 1 day and then tested for 10 days. For each
trial, the total number of arm choices, the number of correct choices be-
fore the first error, and the total number of errors were recorded.
2.15.4. Spontaneous alternation
The apparatus was the same as described for the radial maze with
only 4 arms open. A mouse was released in the central hub of a cross
maze (4 arms) and left free to explore for 10 min. The number and se-
quence of arm entries were recorded. A correct alternation was consid-
ered when no more than one repetition over 5 entries was made.
2.15.5. Fear conditioning
Contextual and trace fear-conditioning protocolswere used. Allmice
were pre-exposed to the test chamber (Ugo Basile, Gemonio, Italy) for
10 min on the 2 days preceding conditioning. During the training
phase of contextual fear conditioning, the trial startedwith 60 s at base-
line followed by presentation of the tone (CS, 15 s) superimposed with
the shock (US) in the last 2 s. During the training phase of the trace fear
conditioning, the trial started with 60 s at baseline followed by presen-
tation of the tone (CS, 15 s), followed 15 s later by the presentation of
the shock US for 2 s. In both protocols, the CS-US presentation was re-
peated 5 times with a 60-s inter-trial intervals. Twenty-four hours
after training conditioning, CTX and CS memory (CUE) were tested.
CTX took place in the same chamber and consisted of 2min observation.
CUE memory took place in a different chamber and consisted of 1 min
without (Bl, baseline) and 1 min with the CS (CUE).5
2.15.6. Spontaneous alternation and fear-conditioning test after 2-deoxy-D-
glucose injection
Gdi1WTandKOmice received an intraperitoneal injection of 10 μL/g
2-DG (Sigma-Aldrich, D-6134) solution 30min before the 1-day sponta-
neous alternation test or fear-conditioning test as described above.
Treated mice were compared with mice injected with saline solution.
2.16. Video tracking and data collection
Animals were video-tracked using the EthoVision 2.3 system
(Noldus Information Technology, Wageningen, the Netherlands;
http://www.noldus.com) using an image frequency of 4.2/s. Raw data
were transferred to Wintrack 2.4 (http://www.dpwolfer.ch/wintrack)
for offline analysis.
For fear-conditioning protocols, animals were video-tracked using
the ANY-maze system (Anymaze, Stoelting, Wood Dale, IL, USA; www.
anymaze.com).
2.17. In vitro electrophysiology
All procedures were approved by the Italian Ministry of Health and
the San Raffaele Scientific Institute Animal Care and Use Committee in
accordance with the relevant guidelines and regulations. Mice (30
days of age) were anaesthetized with an intraperitoneal injection of a
mixture of ketamine/xylazine (100 mg/kg and 10 mg/kg, respectively)
and perfused transcardially with ice-cold artificial cerebrospinal fluid
(ACSF) containing 125 mM NaCl, 3.5 mM KCl, 1.25 mM NaH2PO4, 2
mM CaCl2, 25 mM NaHCO3, 1 mM MgCl2, and 11 mM D-glucose, satu-
rated with 95% O2 and 5% CO2 (pH 7.3). After decapitation, brains
were removed from the skull and 300-μm-thick horizontal slices con-
taining the somatosensory cortex were cut in ACSF at 4 °C using a
VT1000S vibratome (Leica Microsystems). Individual slices were then
submerged in a recording chamber mounted on the stage of an upright
BX51WI microscope (Olympus, Tokyo, Japan) equipped with differen-
tial interference contrast optics. Slices were perfused with ACSF con-
taining 10 μM gabazine (Abcam, Cambridge, UK) to block GABAA
receptors. The ACSF was continuously flowing at a rate of 2–3 mL/min
at 32 °C. Whole-cell patch-clamp recordings were performed in cortical
pyramidal cells using pipettes filled with a solution containing 10 mM
NaCl, 124 mM KH2PO4, 10 mM HEPES, 0.5 mM EGTA, 2 mM MgCl2, 2
mM Na2-ATP, 0.02 mM Na-GTP (pH 7.2, adjusted with KOH; tip resis-
tance: 4–6 MΩ). During recordings, 2-DG was added to the ACSF at a
final concentration of 20 mg/mL and the slice was superfused for 6–8
min before testing its effect on spontaneous EPSCs. For each cell,
AMPA-receptor mediated sEPSCs were recorded in a voltage clamp at
a holding potential of−70mV for 1min. All recordingswere performed
using a MultiClamp 700B amplifier interfaced with a computer through
a Digidata 1440A digitizer (Molecular Devices, Sunnyvale, CA, USA). The
liquid junction potential was not corrected. The series resistance was
partially compensated (40%–50%) using the amplifier control circuit.
Traces were sampled at a frequency of 10 kHz and low-pass filtered at
2 kHz. For each trace, median values of all parameters under study
were calculated and analysed. Datawere acquired using pClamp10 soft-
ware (Molecular Devices) and analysed with Clampfit and GraphPad
Prism (GraphPad, La Jolla, CA, USA).
2.18. Statistical tests
Unless stated otherwise, the statistics are presented as means ±
SEM. Significance levels were ***p < 0.001, **p < 0.01 and *p < 0.05;
tests are indicated with each experiment. For FRET measurements, un-
less stated otherwise, Student's t-test was performed. In behavioural
studies, statistical analyses were done using Statview 5.0 (SAS Institute,
Cary, NC, USA); for electrophysiological data statistical comparisons
were obtained using SigmaStat 3.5 (Systat, San Jose, CA, USA).
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3.1. Abnormal astrocytic glucose metabolism in Gdi1 KO mice
How glial-expressed αGDI improves the health of neurons is pres-
ently unknown, but it is expected to have an impact onmetabolic activ-
ity in astrocytes. To evaluate putative changes in protein expression
caused by the lack of Gdi1, a quantitative proteomic analysis [26] was
carried out on Gdi1 KO and Gdi1 wild-type (WT) astrocytes, resulting
in the identification of 245 proteins to be up- or downregulated in
Gdi1 KO mice compared with WT mice (Supplementary Table 1).
Among these proteins, enzymes involved in glucose metabolism were
significantly altered in Gdi1 KO astrocytes: the astrocyte-specific
enzyme glycogen phosphorylase, which converts glycogen into
glucose-1-phosphate [27], was significantly reduced in Gdi1 KO astro-
cytes compared with WT (p = 0.0001); an opposite trend occurred
with the mitochondrial form of phosphoenolpyruvate carboxykinase
(PEPCK 2, p = 0.025), which catalyses the generation of glucose from
non-carbohydrate carbon substrates such as pyruvate, lactate, glycerol
and glucogenic amino acids involved in gluconeogenesis [28,29].
These data suggest an increased demand for glucose availability by in-
creasing astrocytic glucose metabolism in Gdi1 KO mice.
Because glucose metabolism is essential for normal brain function,
including memory formation, we analysed whether glucose handling
in Gdi1 KO brain differs from that in Gdi1 WT animals. Imaging of
18F-fluorodeoxyglucose ([18F]-FDG), an analogue of D-glucose (2-
deoxy-2-[18F]fluoro-D-glucose) which is transformed to [18F]-FDG-6-Fig. 1. [18F]-FDG autoradiography of Gdi1WT and Gdi1 KOmouse brains. a Representative [18F]
left to right) obtained from Gdi1 WT (top) and Gdi1 KO (bottom) mice. b Total [18F]-FDG-
autoradiography studies. The sum of regional [18F]-FDG uptake measured in Gdi1 KO animals
uptake in discrete brain areas of Gdi1 WT (n = 6) and Gdi1 KO mice (n = 9). Black and w
respectively. [18F]-FDG uptake was calculated as a percentage of the injected dose per area of b
6
phosphate by hexokinase and no further metabolized [30], revealed
an increased [18F]-FDG radioactivity uptake signal in whole 3-months-
old Gdi1 KO brains compared with WT (p=0.05, Fig. 1a, b). In particu-
lar, the strongly enhanced autoradiographic signal in Gdi1 KO murine
brain slices was specific for cortex (p = 0.02), hippocampus (p =
0.04) and cerebellum (p= 0.03) brain regions, but not for the striatum
and thalamus (Fig. 1c). These results indicate a specific role ofαGDI in D-
glucose utilization circumscribed to defined brain areas.
To verify the direct involvement of αGDI in altered D-glucose ho-
meostasis, we first evaluated glucose tolerance and insulin sensitivity,
fasting and non-fasting glucose levels. Then, brain astrocytes, an impor-
tant site of aerobic glycolysis in the brain [31], were studied using the
glial fibrillary acidic protein (GFAP) marker to quantify the total
astrocytic cell density and analysing the density of the most abundant
D-glucose transporter GLUT1. No differences in systemic glucose meta-
bolic readouts were detected between 3-month-old Gdi1 WT and KO
mice (Supplementary Fig. 1a–c). Similarly, by immunofluorescence on
Gdi1WT and KO cortical brain slices, no alterations between genotypes
were detected on GFAP-immunolabelled cells per nm2, as well as
GLUT1-positive cells per nm2 (Supplementary Fig. 1d). Moreover, the
analysis of GLUT1 surface expression by biotinylation assay on Gdi1
WT and KO astrocytic cell cultures showed no alterations between ge-
notypes (Supplementary Fig. 1e, f). However, these results suggest
that the glucose–related metabolic readouts and the canonical
glucose-related brain structures appear unaffected by the lack of Gdi1,
therefore we further tested whether the regulation of astroglial aerobic
glycolysis was altered in the two genotypes.-FDG autoradiography images of coronal brain sections (antero-posterior orientation from
uptake of the brain areas of Gdi1 WT (n = 6) and Gdi1 KO mice (n = 9) obtained in
was significantly higher compared with that measured in Gdi1 WT animals. c [18F]-FDG
hite bars represent [18F]-FDG uptake in the brain areas of Gdi1 WT and Gdi1 KO mice,
rain analysed (%ID/mm2) and expressed as mean ± SEM. Student's t-test *p < 0.05.
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L-lactate modulation of cAMP signalling in Gdi1 KO astrocytes
We assessed whether the increased D-glucose utilization in Gdi1 KO
murine brain (Fig. 1) was associated with changes in the regulation of
aerobic glycolysis in astrocytes. For this, we measured cytosolic levels
of free D-glucose ([glucose]i), a parameter determined by D-glucose up-
take from the extracellular space, and the rate of cellular D-glucose con-
sumption. An increase in [glucose]i can be recorded in astrocytes under
noradrenaline (NA) stimulation, due to facilitated extracellular D-
glucose uptake [32], requiring sequestration in the endoplasmic reticu-
lum [33] and stimulated glycogenolysis [20]. We used the fluorescence
resonance energy transfer (FRET)-based nanosensor FLII12PGLU-
700μΔ6 [20] to monitor [glucose]i in Gdi1 KO and Gdi1 WT astrocytes.
The results revealed that in Gdi1 KO astrocytes, the amplitude of the
NA-mediated increase in [glucose]i was reduced by ~2-fold compared
with Gdi1 WT astrocytes; from 27.1% ± 4.1% (mean ± standard error
of the mean [SEM], 14 responsive cells [35%] of 42 cells) to 16.6% ±
2.6% in Gdi1 KO astrocytes (20 responsive cells [47%] of 42 cells; one-
way ANOVA, p< 0.05; Fig. 2a, left graph, and b, curve fitting parameters
in Supplementary Table 2). However, the time constant (τ), a measureFig. 2. Noradrenaline-induced increase in cytosolic D-glucose is reduced in astrocytes from
concentration ([glucose]i), presented as changes in EYFP/ECFP fluorescence (FRET) signal in
Experiments were performed in control (left) and in 2 mM L-lactate pre-treated (Lac) astr
responsive out of 20 cells for Lac + NA) and Gdi1 KO animals (white; 20 responsive out of 42
cultures. Changes in the FRET signal are expressed as percentages relative to the initial value
equation parameters). b Mean amplitudes (ΔFRET) and time constants (τ) of NA-induced incr
mM L-Lactate (NA and Lac + NA, respectively) determined by fitting exponential functions (
cAMP-dependent PKA activity presented as changes in YFP/CFP fluorescence (FRET) signa
Experiments were performed in control (left) and in 2 mM L-lactate pre-treated (Lac) astr
responsive out of 11 cells [Lac]) and Gdi1 KO animals (white; 11 responsive out of 11 cells [c
and 4 Gdi1 KO animals for NA stimulation; and 4 Gdi1WT and 5 Gdi1 KO animals for NA stimu
to the curves (see Supplementary Table 2 for equation format). d Mean amplitudes (ΔFRET) a
KO astrocytes in the absence and presence of pre-treatment with 2 mM L-lactate (NA and La
Table 2. Error bars in graphs and bar charts denote the mean ± SEM; asterisks in bar charts in
7
of the kinetics of the NA-mediated increase in [glucose]i, was similar
in Gdi1 WT and KO astrocytes (Fig. 2a, left graph, and b). As these re-
sponses were measured at the same extracellular D-glucose concentra-
tion, these results are consistent with the view that D-glucose
utilization is facilitated in Gdi1 KO compared with Gdi1 WT astrocytes.
Facilitated D-glucose utilization is expected to result in accelerated
production of L-lactate, which can then exit astrocytes through mono-
carboxylate transporters (MCTs [34]) and further enhance astroglial
glycolysis through a receptor-like mechanism [35]. Indeed, in the pres-
ence of 2 mM extracellular L-lactate, a physiological value in the brain
[36], NA elicited a reduced amplitude in [glucose]i inGdi1WTastrocytes
(11.4% ± 2.2%; 10 responsive (50%) of 20 cells; Fig. 2a, right graph, and
b), significantly lower in comparison with responses in the absence of
extracellular L-lactate (Fig. 2a, left graph, 27.1% ± 4.1%), and consistent
with facilitated D-glucose utilization in Gdi1 KO astrocytes. In the pres-
ence of 2 mM L-lactate, the amplitude of the NA-induced increase in
[glucose]i in Gdi1 WT responsive cells was similar to that recorded in
Gdi1 KO astrocytes in the absence of 2 mM L-lactate (Fig. 2a, left
graph, and b).Moreover, in the presence of 2mMextracellular L-lactate,
the kinetics (τ) of NA-induced responses in Gdi1 WT cells was signifi-
cantly reduced; from 253.5 ± 39.5 s (mean ± SEM; n = 12) in theGdi1 KO versus WT animals. a Mean time-dependent changes in cytosolic D-glucose
astrocytes expressing FLII12PGLU-700 μΔ6 on noradrenaline stimulation (NA, 200 μM).
ocytes (right), isolated from Gdi1 WT (black; 14 responsive out of 42 cells for NA, 10
cells for NA, 8 responsive out of 12 cells for Lac + NA), each obtained on 3 independent
s. Single exponential functions were fitted to the curves (see Supplementary Table 2 for
ease in [glucose]i from Gdi1WT and Gdi1 KO astrocytes in the absence and presence of 2
see parameters in Supplementary Table2). c Mean time-dependent changes in cytosolic
l in astrocytes expressing cAMP/PKA nanosensor AKAR2 on NA stimulation (100 μM).
ocytes (right) isolated from Gdi1 WT (black; 12 responsive out of 12 cells [control], 11
ontrol], 12 responsive out of 12 cells [Lac]). Cell cultures were prepared from 5 Gdi1 WT
lation on 2 mM L-lactate pre-treated astrocytes. Single exponential functions were fitted
nd time constants (τ) of NA-induced increase in cAMP/PKA activity in Gdi1 WT and Gdi1
c + NA, respectively) determined by fitting exponentials; parameters in Supplementary
dicate significant differences (one way ANOVA, *p < 0.05).
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< 0.05; Fig. 2b) in the presence of 2 mM L-lactate. However, it was sim-
ilar to the τ value recorded in Gdi1 KO astrocytes in the presence of 2
mM extracellular L-lactate: 129.7± 27.1 s (mean± SEM, n=8 respon-
sive cells (67%) of 12 cells; Fig. 2b, Lac + NA). These data indicate that
changes in the physiological levels of extracellular L-lactate, an extracel-
lular signal [37], might facilitate D-glucose utilization in Gdi1WT astro-
cytes to the same extent as in Gdi1 KO in the absence of added
extracellular L-lactate, suggesting that the facilitated utilization of D-
glucose in Gdi1 KO cells was due to changed regulation of aerobic
glycolysis.
Because cytoplasmic cAMP/PKA signalling, mediated by β-
adrenergic receptors, is involved in the regulation of glycolysis [38],
we next used the FRET-based nanosensor AKAR2 to monitor cytosolic
cAMP-dependent PKA (cAMP/PKA) activity [39]. The amplitude of
cAMP-dependent PKA activity, stimulated by the addition of NA, was
similar in both types of astrocytes (Fig. 2c), despite the increased abun-
dance of β1-adrenergic receptors in Gdi1 KO compared with WT cells
(Supplementary Fig. 2a, b). However, the time constant τ of the increase
in PKA activity was significantly shorter in Gdi1 KO astrocytes than in
Gdi1 WT cells (mean ± SEM in seconds; Gdi1 WT, 46.8 ± 3.0 s, n =
12 responsive cells (100%); Gdi1 KO, 26.0 ± 5.0 s, n = 11 responsive
cells (100%); one-way ANOVA, p<0.05; Fig. 2d, right graph). Moreover,
in the presence of 2 mM extracellular L-lactate (Lac + NA), the cAMP
signalling was potentiated by almost 2-fold, however only in Gdi1 KO
astrocytes, where the amplitude relative to the baseline (in %) was sig-
nificantly larger than the response recorded in the absence of extracel-
lular L-lactate (mean ± SEM in %; Gdi1 KO, 18.9% ± 2.0%, n = 12
responsive cells (100%); Gdi1 WT, 11.7% ± 2.0%, n = 11 responsive
cells (100%); Student's t-test; p < 0.05; Fig. 2c, right graph, and d).
These results indicate that cAMP signalling was altered in Gdi1 KO
cells and that these cells weremore sensitive to changes in extracellular
L-lactate (Fig. 2a, c), a putative signal regulating glycolysis in astrocytes
[35].
Thus, the extracellular L-lactate-mediated potentiation of NA-
induced cAMP signalling in Gdi1 KO astrocytes (Fig. 2c, d) was likely
due to enhanced cAMP production, not only via adrenergic receptors
but also L-lactate receptors [35,37,40], because in the absence of NA,
the addition of extracellular L-lactate (2 mM) on its own produced a
small but significant increase in cAMP signalling in Gdi1 KO but not in
Gdi1WT controls (Supplementary Fig. 3).
In addition to cAMP, changes in the cytosolic levels in Ca2+ also reg-
ulate glycolysis [38] and may contribute to the increased D-glucose uti-
lization in Gdi1 KO astrocytes observed in these experiments. However,
this is unlikely, because addition of extracellular L-lactate (10 mM) had
no effect on cytosolic levels of Ca2+ in Gdi1 WT and in Gdi1 KO
astrocytes, as monitored by calcium fluorescence indicator Fluo-4 AM
(Supplementary Fig. 4a–c). Collectively, these results indicate that the
NA-dependent increase in D-glucose utilization in the presence of extra-
cellular L-lactate in Gdi1 KO astrocytes is associated with facilitated
cAMP, but not with Ca2+ signalling.3.3. Intact capacity of Gdi1 KO astrocytes to produce and transport L-lactate
through MCTs
We next asked whether the cAMP signalling involving the putative
L-lactate receptor mechanisms [41] is affected in Gdi1WT and Gdi1 KO
astrocytes. For this, extracellular L-lactate (20 mM; Fig. 3a) or 3-
chloro-5-hydroxybenzoicacid (3-Cl-5-OH-BA, 0.5 mM; Fig. 3b), a selec-
tive GPR81 L-lactate receptor agonist [42], were used while monitoring
the cAMP-dependent PKA activity. In Gdi1 WT and KO astrocytes
exposed to 20 mM L-lactate, a similar increase in cAMP-dependent
PKA activity was recorded (Fig. 3a). Interestingly, in Gdi1 KO but not
in Gdi1 WT astrocytes, the exposure to extracellular 2 mM L-lactate in-
creased cAMP signalling (Supplementary Fig. 3a). These results indicate8
that putative L-lactate receptor(s)-mediated cAMP signalling is not af-
fected at 20mM(Supplementary Fig. 3b), but only at 2mMextracellular
L-lactate (Supplementary Fig. 3a) in Gdi1 KO cells.
However, when [glucose]i was monitored, the application of 20 mM
extracellular L-lactate elicited a similar amplitude between genotypes
(Fig. 3c), but with a 2-fold slower increase in Gdi1 KO (mean ± SEM
in seconds; Gdi1 WT, 92.9 ± 23.8 s, n = 11; Gdi1 KO, 184.2 ± 32.6 s,
n = 15; Student's t-test, p < 0.05; Fig. 3c). These data are consistent
with the view that D-glucose utilization is facilitated in Gdi1 KO astro-
cytes, as observed when cells were stimulated by NA (Fig. 2a).
L-Lactate is an end product of glycolysis andmay be released from as-
trocytes, which can in turn stimulate astrocytes to producemore L-lactate
through astroglial surface L-lactate receptors, or L-lactate may enter the
cells through lactate transporters/channels and interfere with glycolysis
[35]. Measurements of cytosolic levels of L-lactate ([lactate]i) by the
FRET-based nanosensor Laconic [22] revealed that by exposing the cells
to L-lactate (20 mM), there was no difference in the time course or in
the amplitude of [lactate]i (Fig. 3d). This indicates that the transport of
L-lactate through membrane transporters/channels into astrocytes and/
or L-lactate receptor-mediated increase in intracellular L-lactate produc-
tion was not significantly affected in Gdi1 KO astrocytes. We next ad-
dressed whether monocarboxylate L-lactate transporters, MCT1 and
MCT4, were impaired in Gdi1 KO astrocytes by immunofluorescence on
Gdi1 KO and Gdi1WT astrocytes. The percentage of MCT1 andMCT4 pro-
tein expression in astrocytes was unaltered (Fig. 3e).
Next, to evaluate whether the resting rate of L-lactate production
was altered in Gdi1 KO compared with Gdi1 WT astrocytes, we
monitored [lactate]i increases in the presence of α-cyano-4-
hydroxycinnamate (CHC, 6 mM), a blocker of membrane MCTs. In
the absence of L-lactate exchange through the plasma membrane,
the predominant pathway available for increase in [lactate]i is con-
sidered to be glycolytic L-lactate production [35]. Although cytosolic
L-lactate levels may be coupled to mitochondrial metabolism in
astrocytes [43,44], in the presence of MCT blockers, the increase in
[lactate]i is comparable with the rate of aerobic glycolysis at rest.
After the application of CHC, we observed an exponential increase
in [lactate]i. Fitting an exponential curve revealed that the amplitude
(c) and the kinetics (expressed by the time constant τ) were similar
in Gdi1 WT and KO astrocytes (Supplementary Table 4).
Together, these results indicate that in Gdi1 KO astrocytes, facilitated
D-glucose utilization persists, with no impact on the capacity of these
cells to produce and transport L-lactate through MCT transporters.
3.4. Generation of an astrocyte-inducible Gdi1 conditional null mouse
To test how altered astroglial D-glucosemetabolism contributes to the
previously reported Gdi1 KO cognitive dysfunctions [7], we generated an
inducible Gdi1 KO mouse carrying the Gdi1 deletion only in adult astro-
cytes, and we tested for its behavioural performance. To inactivate Gdi1
prevalently in astrocytes, the previously generated heterozygous Gdi1lox/
X female mice [8] were crossed with transgenic GLAST::CreERT2 male
mice (obtained from M. Götz, Munich, Germany), a tamoxifen-inducible
form of Cre-recombinase under the astrocyte-specific glutamate trans-
porter (GLAST) promoter, known to allow gene deletion in adult astro-
cytes at a precise time [23]. The breeding generated GLAST::CreERT2+/
Gdi1lox/Y male mice (referred to as GlastGdi1flox/Y for astrocyte-specific
Gdi1 KO), which were compared with the Gdi1X/Y WT male littermate
mice. Gdi1 tamoxifen-inducible astrocytic inactivation was assessed in
150-day-old (P) GlastGdi1flox/Y and WT cortical brain slices. Tamoxifen
toxicity was excluded because of the comparable GFAP-positive astrocyte
density between genotypes (Fig. 4a, b). In situ hybridization and immu-
nofluorescence were coupled to reveal the distribution of Gdi1 mRNA in
GFAP-positive astrocytes (Fig. 4a, b). Comparing the number of Gdi1 and
GFAP double-positive cells in GlastGdi1flox/Y and Gdi1X/Y mice, we found
that 58% of astrocytes showed Gdi1 inactivation (mean ± SEM as the
Fig. 3. Reduced rate of [glucose]i increase upon extracellular L-lactate stimulation in Gdi1 KO astrocytes. a–b Mean time-dependent changes in cytosolic cAMP/PKA activity (YFP/CFP
fluorescence (FRET) signal; AKAR2 nanosensor) elicited (a) by 20 mM L-lactate (Lac) and (b) by 0.5 mM GPR81 L-lactate receptor agonist 3-chloro-5-hidroxybenzoat (3Cl-5-OH-BA) in
Gdi1WT astrocytes (black; 7 responsive out of 13 cells for Lac, 5 responsive out of 8 cells for 3Cl-5-OH-BA) and Gdi1 KO cells (white; 9 responsive out of 17 cells for Lac, 11 responsive
out of 12 cells for 3Cl-5-OH-BA); cultures were obtained from 4 Gdi1 WT and 5 KO animals for 20 mM Lac and from 2 Gdi1 WT and 2 KO animals for 3Cl-5-OH-BA. Exponential
functions were fitted to the curves (Supplementary Table 3); parameters are in histograms to the right in (a) and (b). The onset of FRET response upon 3Cl-5-OH-BA stimulation was
28.0 ± 13.0 s in Gdi1 WT, shorter than 43.6 ± 7.2 s in Gdi1 KO astrocytes. c-d Mean time-dependent changes in (c) [glucose]i (EYFP/ECFP fluorescence (FRET) signal; FLII12PGLU-700
μΔ6 nanosensor) in Gdi1 WT (black; 11 responsive out of 12 cells) and Gdi1 KO astrocytes (white; 15 responsive out of 22 cells) and (d) [lactate]i (mTFP/Venus fluorescence (FRET)
signal; Laconic nanosensor) in Gdi1 WT (black; 24 responsive out of 25 cells) and Gdi1 KO astrocytes (white; 22 responsive out of 24 cells), elicited by 20 mM extracellular L-lactate
(Lac); cells were from at least 3 independent Gdi1 WT and KO cultures. Parameters of fitted exponentials (Supplementary Table 3) are in histograms to the right. The amplitude of
[glucose]i increase was similar in Gdi1 WT and KO astrocytes, whereas time constant was >2-fold larger in Gdi1 KO versus Gdi1 WT astrocytes. Changes in the FRET signal in (a–d) are
expressed as percentages relative to the initial values. e Representative images of Gdi1 WT and KO astrocytes labelled with antibodies against MCT1 or MCT4. Scale bar, 20 μm. Bar
charts of relative anti-MCT1-, anti-MCT4-positive cell cross-section area (S; i.e. number of green fluorescence pixels, threshold >20% of maximal fluorescence) versus total cell cross-
section area (cell S; i.e. number of all pixels) in percent (%) in Gdi1 WT and KO astrocytes; MCT1 experiment, 3 and 4 Gdi1 WT and Gdi1 KO independent cultures, respectively; MCT4
experiments, 6 and 7 Gdi1 WT and KO independent cultures, respectively. Error bars are means ± SEM, Mann-Whitney U test, *p < 0.05.
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GlastGdi1flox/Y, 0.34±0.05; n=3mice per genotype; Student's t-test, p=
0.01; Fig. 4a, b), in agreement with the Cre-recombinase efficiency de-
scribed previously [23].
The experiments also demonstrated that the lack of Gdi1 is specifi-
cally limited to the astrocytes, without neuronal involvement, because
by electron microscopy in the CA1 hippocampal terminals, we found
no alterations in synaptic button morphology and synaptic vesicle9
density (Table 1), as has been shown to be the major morphological
phenotype observed in Gdi1 KO mice [45].
3.5. GlastGdi1flox/Y mice are specifically impaired in working memory but
not in associative memory
Itwas previously shown that adultGdi1KOmice aswell as neuronal-
specific CaMKII-Cre+-Gdi1flox/Ymice did not have defects in emotional or
Fig. 4. Characterization ofGlastGdi1flox/Ymice. a Left panel is a lowmagnification coronal section stained with DAPI. Thewhite rectangle outlines the hippocampal region analysed in (a1)–
(a4). Scale bar, 1 mm. DG, dentate gyrus; CA1, hippocampal CA1 region; LA, lateral amygdala; MGm, medial geniculate nucleus. a1–a4 Representative images of Gdi1 in situ hybridization
(black), GFAP immunofluorescence (green) and DAPI (purple). (a1) correspond to Gdi1X/Y and (a2) is a magnification outlined by the white square in (a1); the same for GlastGdi1flox/Y (a3
and a4).White arrows indicate GFAP-positive cells co-localizing with Gdi1; red arrows indicate GFAP-positive cells that are negative for Gdi1. Scale bars, 100 μm(a1 and a3); 50 μm(a2 and
a4). b Histograms represent the mean ± S.E.M of the GFAP-positive cells and the colocalization between GFAP and Gdi1-positive cells/nm2 of the CA1 region of stratum radiatum of the
hippocampus from Gdi1X/Y (n= 3; black) and GlastGdi1flox/Y (n= 3; white) mice. Student's t-test, **p< 0.01.
Table 1
Electron microscopy quantification of pre-synaptic parameters in the CA1 hippocampal
region of GLASTGdi1lox/Y versus GlastGdi1flox/Y mice.
GLASTGdi1lox/Y GlastGdi1flox/Y
No. of mice analysed 3 3
No. of synapses analysed 243 261
Synapsis density (no./μm2) 0.40 ± 0.01 0.40 ± 0.01
Pre-synaptic area (μm2) 0.23 ± 0.01 0.24 ± 0.01
PSD length (μm) 0.30 ± 0.01 0.30 ± 0.01
SV density (no. SV/μm2) 106 ± 3.55 107 ± 3.44
Statistical analysis was performed using the unpaired Student's t-test GLASTGdi1lox/Y ver-
sus GlastGdi1flox/Y. PSD, postsynaptic density; SV, synaptic vesicle.
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forebrain-dependent forms of short-termmemory, theworking and as-
sociative fear-related memory, the radial maze and trace fear-
conditioning tests [7,8,45], respectively. To assess whether astrocytic
αGDI ablation in postnatal life plays a key role in working and associa-
tive fear-related memory formation, P90 Gdi1X/Y and GlastGdi1flox/Y
male littermate mice were subjected to the following tests: novelty
test to assess explorative behaviour, water maze test to evaluate spatial
memory, 8-arm radial maze to analyse working and procedural mem-
ory, and fear conditioning to estimate associative memory. To exclude
any toxic effects due to Cre-recombinase expression and/or tamoxifen
injection, we used WT male mice for Gdi1 (Gdi1X/Y) but carrying the
GLAST:CreERT2 transgene (GlastGdi1X/Y) treated with tamoxifen and
tested at P90. GlastGdi1X/Y mice were indistinguishable from the Gdi1X/
Y mice in all the tests (data not shown).
Then,we first assessed exploratory behaviour and spatialmemory in
Gdi1X/Y and GlastGdi1flox/Ymale littermates by the novelty test andwater
maze, respectively. Both groups showed normal explorative behaviour,
as shown for the distance travelled (Fig. 5a), as well as intact spatial
memory scored by the time to reach the hidden platform in the water
maze task (Fig. 5b) or in the probe trial (Fig. 5c). Because similarFig. 5. Behavioural analysis ofGlastGdi1flox/Ymice. a Distance travelled during the novelty test by
hidden platform by GlastGdi1flox/Y (n = 10) and Gdi1X/Y (n = 7) mice during 5 consecutive day
phase. oo, opposite old goal position; ol, left side of old goal position; og, old goal; or, right si
and Gdi1X/Y (n = 26) mice in the 10 consecutive days. e Number of correct arm choices b
alternation test done by GlastGdi1flox/Y (n = 9) and Gdi1X/Y (n = 6) mice. g–i Contextual (
animals. g Percentage (%) of freezing displayed during the 15 s of the 5 CS presentations in t
Trace fear conditioning assessed in GlastGdi1flox/Y (n = 19) and Gdi1X/Y (n = 15) animals. j Per
session, (k) during the context memory test and (i) during the CUE test. Data points and his
bars and circles represent GlastGdi1flox/Y. ANOVA, *p < 0.05.
10performances were also observed in Gdi1 KO mice as well as
neuronal-specific CaMKIIGdi1flox/Y mice, we concluded that the lack of
αGDI in neurons or astrocytes did not affect exploration and spatial
memory.
Next, we assessed spatial working memory by subjecting the animals
to the 8-arm radial maze and the spontaneous alternation test. As shown
in Fig. 5d, in the 8-arm radial maze, the total number of errors declined
over the 10 days of training in both Gdi1X/Y and GlastGdi1flox/Y; however,
acquisition in mutant mice was significantly slower than in controls
(ANOVA repeated measures for genotype effect F[1,51] = 6.6, p =
0.01), and they did not reach the performance level of Gdi1X/Y mice. Al-
though Gdi1X/Y mice eventually reached nearly perfect performance (7
out of a maximum number of 8 correct successive arm visits; Fig. 5e),
GlastGdi1flox/Y mice barely scored above chance level (5.5 correct succes-
sive armvisits after 10 days of training; ANOVA repeatedmeasures for ge-
notype effect F[1,51] = 6.5, p = 0.01; Fig. 5e). Accordingly, in the
spontaneous alternation test, a significant difference was observed be-
tween genotypes in the percentage (%) of correct alternation (ANOVA fac-
torial analysis for genotype effect F[1,13] = 9.1, p = 0.01; Fig. 5f). Thus,
the lack of αGDI in astrocytes affects spatial working memory.
One of the most robust phenotypes that we always observed in the
Gdi1 KO mice was the specific inability to associate stimuli across a
short time interval, as we showed in the trace fear-conditioning para-
digm (TFc) but not in the standard protocol (termed delay or contextual
conditioning, DFc) [7]. We then subjected the animals to both para-
digms and surprisingly, GlastGdi1flox/Y mice showed intact associative
learning in both tests (Fig. 5g–l). No difference was observed between
Gdi1X/Y and GlastGdi1flox/Y mice in any of the tests performed: the ability
to associate a tone, a conditioned stimulus (CS), with a foot shock, an
unconditioned stimulus (US), during the training session (Fig. 5g, j);
as well as 24 h later when tested for context memory (Fig. 5h, k) and
the cue memory test (Fig. 5i, l).
These results revealed that GlastGdi1flox/Y mice exhibit selective im-
pairment of working memory ability, demonstrating that althoughGlastGdi1flox/Y (n=10) and Gdi1X/Y (n=8)mice. b, cWaterMaze test. b Time to reach the
s. c Annulus crossing during the probe trial in the first 30 s of the first day of the reversal
de of old goal. d, e Radial maze test. d Number of errors done by GlastGdi1flox/Y (n = 27)
efore the first error. f Percentage (%) of correct alternations during the spontaneous
delay) fear-conditioning test assessed in GlastGdi1flox/Y (n = 12) and Gdi1X/Y (n = 13)
he training session, (h) during the context memory test and (i) during the CUE test. j–l
centage (%) of freezing displayed during the 15 s of the 5 CS presentations in the training
tograms represent the means ± SEM. Black bars and circles represent Gdi1X/Y and white
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neurons, working memory ability relied on αGDI-independent func-
tion(s) in neurons and astrocytes (Table 2). Moreover, we could11speculate that alteration in working memory ability could be triggered
by facilitated D-glucose utilization in Gdi1 KO mice (Fig. 1), as demon-
strated in isolated astrocytes (Figs. 2 and 3).
Table 2
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, no differences between genotypes; , impairment in learning, compared to Gdi1 WT.
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formance in Gdi1 KO mice
We then tested whether impaired glucose metabolism, demon-
strated by the more efficient use of D-glucose in Gdi1 KO astrocytes
(Figs. 2a, 3b), consistent with an enhanced [18F]-FDG signal (Fig. 1),
was the key process underlying the working memory defect in Gdi1
KO mice, as also shown to be specific in GlastGdi1flox/Y mice (Fig. 5d–f).
The replacement of 3 mM D-glucose in the extracellular solution with
0 mM D-glucose or 3 mM 2-deoxy-D-glucose (2-DG), which enters
cells through glucose transporters and blocks glycolysis [12], greatly re-
duced the NA-induced increase in [lactate]i in rat cortical astrocytes
(Supplementary Table 5). We then treated Gdi1 KO and WT littermate
mice with 2-DG and compared them with non-treated (NT) groups in
the spontaneous alternation working memory test and the trace fear-
conditioning associative test as a negative control. We also treated
Gdi1KOandWTmouse littermateswith 3Cl-5-OH-BA, a GPR81 receptor
agonist [42], which increases L-lactate production in astrocytes [35].
As shown in Fig. 6a, injection of 2-DG significantly impaired the
score for the spontaneous alteration test of Gdi1WT animals compared
with NT Gdi1WTmice (ANOVA factorial analysis for 2-DG versus NT ef-
fect on WTs: F[1,42] = 28.3, p < 0.0001). In contrast, the 2-DG treat-
ment significantly improved the performance of Gdi1 KO mice
compared with NT Gdi1 KO mice (ANOVA factorial analysis for treat-
ment effect on KO: F[1,41] = 9.6, p = 0.003); in particular, Gdi1 KO 2-
DG-treated mice reached the performance level of NT Gdi1 WT mice.
The injection of 3Cl-5-OH-BA had no effect on Gdi1 KO mice and wors-
ened the score for the spontaneous alteration test of treated Gdi1 WT
compared with NT Gdi1 WT (ANOVA factorial analysis for 3Cl-5-OH-
BA-WT versus NT-WT effect: F[1,37] = 17.08, p = 0.0002; Fig. 6a).
Conversely, the treatment of Gdi1 KO and WT mouse littermates
with 2-DG compared with NT groups in the trace fear-conditioning
test had no significant effect onGdi1WTmice in any of the test sessions.
Instead, injection of 2-DG in Gdi1 KOmice improved their performance
slightly during the training and context sessions but not during the tone
test comparedwith NT Gdi1 KOmice (ANOVA repeatedmeasures for 2-
DG KO versus NT-KO training effect for CSs: F[1,23] = 5.8, p = 0.02;
context memory [CTX] effect: F[1,23] = 4.8, p = 0.03; Fig. 6b–d).
These results strongly support the view that facilitated utilization of
D-glucose in astroglial aerobic glycolysis has a negative impact onwork-
ingmemory acquisition, but not on trace fear conditioning, as shown by
the performance of Gdi1 WT mice under 2-DG treatment.
We then investigated how 2-DG treatment affects cortical gluta-
matergic transmission, by recording spontaneous excitatory12postsynaptic currents (sEPSCs) in cortical slices from 2-DG-treated
and NT P30 Gdi1 KO and WT littermate mice using whole-cell voltage-
clamp recordings (Fig. 6e–h). Compared with WT, Gdi1 KO neurons
showed decreased average frequency and increased average amplitude
of sEPSCs (mean±SEM for frequency in Hz; Gdi1WT, 6.6± 0.7 Hz, n=
10; Gdi1 KO, 4.8 ± 0.5 Hz, n = 11 cells; unpaired Student's t-test, p =
0.03; Fig. 6f; mean ± SEM for amplitude in pA; Gdi1 WT, −7.5 ± 0.9
pA, n = 12; Gdi1 KO,−10.6 ± 1.1 pA, n = 10 cells; unpaired Student's
t-test, p = 0.04; Fig. 6g), without showing any changes in the decay
time constant (Fig. 6h). Extracellular perfusion with 2-DG caused a sig-
nificant increase in the average sEPSC frequency in Gdi1 KO but not in
WT neurons (mean ± SEM for frequency in Hz; NT-KO, 5.1 ± 0.6 Hz;
2-DG-KO, 7.4 ± 0.6 Hz, n = 11; paired Student's t-test, p = 0.013;
Fig. 6f). Conversely, the peak amplitude and decay time constant were
unaffected by 2-DG in both genotypes (Fig. 6g, h). These results indicate
that presynaptic glutamate release is reduced in Gdi1 KO neurons in
comparison with Gdi1 WT and is rescued after acute treatment with
2-DG.
4. Discussion
In this study, we describe a new phenotype associated with Gdi1 de-
letion in mouse brain related to alterations in astrocytic glucose metab-
olism. 18[F]-FDG imaging in Gdi1 KO mouse brain revealed increased
glucose uptake in specific regions. In addition, proteomic experiments
on Gdi1 KO astrocytes have shown that enzymes involved in the mobi-
lization/production of glucose are modulated differently in Gdi1 KO
mice, suggestive of increased D-glucose utilization. This was confirmed
by single astrocyte FRET experimentsmeasuring cAMP/PKA activity, cy-
tosolic levels of D-glucose ([glucose]i) and L-lactate ([lactate]i), which
revealed that D-glucose utilization was facilitated in Gdi1 KO astrocytes
compared with Gdi1 WT astrocytes.
L-Lactate is an important product of astrocytic aerobic glycolysis,
which cannot be easily produced in neurons, but represents a fuel for
neuronal oxidative metabolism [46]. Interestingly, the capacity of L-
lactate export from Gdi1WT and KO astrocytes was similar, determined
by unchanged expression of MCT1 and MCT4 monocarboxylic acid
transporters by immunocytochemistry. Thiswas confirmed functionally
bymonitoring [lactate]i while exposing astrocytes to 20mMextracellu-
lar L-lactate, although the rate of L-lactate-induced increase in [glucose]i
was >2-fold slower in Gdi1 KO versus WT astrocytes.
The increased sensitivity of cAMP signalling in Gdi1 KO astrocytes to
extracellular L-lactate (2 mM) likely arises from an altered set and/or
density of receptors in Gdi1 KO versusWT astrocytes. These membrane
Fig. 6.2-Deoxy-D-glucose treatment improves cognition inGdi1KOmice. a Percentage (%) of correct alternations of 2-deoxy-D-glucose (2-DG)-treatedWT (n=18) andGdi1KO (n=13)
mice, 3-chloro-5-hidroxybenzoic acid (3Cl-5-OH-BA)-treatedWT (n= 13) and Gdi1 KO (n= 12) mice compared with non-treated (NT)WT (n= 26) and Gdi1 KO (n= 30) mice. Data
are expressed asmeans ± SEM. b–d Percentage (%) of freezing during the training (b), context (c) and cue (tone) (d) trace fear-conditioning test of 2-DG-treatedWT (n= 13) and Gdi1
KO (n= 12) mice compared with non-treated (NT)WT (n= 16) and Gdi1 KO (n= 13) mice. e Representative traces showing sEPSCs recorded in pyramidal neurons of slices from Gdi1
KO mice in NT conditions (black trace) and after bath perfusion with 2-DG (grey trace). f–h Summary data for EPSC parameters obtained from WT and KO cortical neurons. Data are
expressed as means ± SEM. ANOVA was used for behavioural test; Student's t-test was used for electrophysiological parameters; *p < 0.05, **p < 0.01, ***p < 0.001.
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part, the mechanism for an altered array of surface membrane recep-
tors, as determined by monitoring the abundance of adrenergic recep-
tors, is likely linked to the general change in vesicle dynamics
described in Gdi1 KO astrocytes previously [47]. In addition to defective
vesicle network dynamics, the more sensitive L-lactate-mediated in-
crease in cAMP in Gdi1 KO astrocytesmight also be due to putative olig-
omerization between different G-protein coupled (GPCR) receptor
types [35,48]. Moreover, this can also be due to the overexpression of
L-lactate-sensitive receptors.
The identity of L-lactate receptors in the brain has been considered in
primary cortical neurons, where extracellular L-lactate modulates neu-
ronal activity via a receptor-mediated process [49], recently described
as the HCAR 1 (GPR81) receptor [50], the canonical L-lactate receptor,
originally discovered in adipocytes [51]. However, this receptor is un-
likely present in the locus coeruleus neuronal somata [40],where amul-
titude of L-lactate receptors may play a role [41].
The nature of L-lactate receptors in astrocytes is also unknown, but
unlikely involves GPR81, which has been shown to reduce the levels
of cAMP in adipocytes through an autocrine loop [51]. In astrocytes,
the application of selective agonists for GPR81 resulted in an increase
in cAMP, even in the absence of GPR81, indicating novel, yet unidenti-
fied L-lactate receptors in these cells [35]. The results in this study are
consistent with these findings, both at the cell level and at the level of
behaviour, where application of the GPR81 agonist 3Cl-5-OH-BA in-
creased cAMP activity (Fig. 3b), a stimulus for aerobic glycolysis in as-
trocytes [31], and tended to worsen the behavioural phenotype of
correct alteration (Fig. 6a), respectively.
The overall aim of our studywas to test the hypothesis that previously
observed cognitive impairment of Gdi1 KO animals arises not only from a
deficit in synaptic glutamate release of excitatory neurons but also from a
metabolic defect in astrocytes. This was confirmed by generating an in-
ducibleGdi1 deletion selectively in astrocytes, which revealed a particular
role of astrocyticαGDI in anterior forebrain-related workingmemory ac-
quisition. Many studies have been performed to establish the astrocytic
role in animal behaviour, independently addressing the neuron-
astrocyte network (for a review seeOliveira et al. [9]). Our results strongly
support the view that the significantly increased [18F]-FDG radioactivity
uptake in hippocampus and cortical brain regions and the facilitated uti-
lization of D-glucose in astrocytes, through aerobic glycolysis, has a nega-
tive impact on working memory acquisition in the neurodevelopmental
disease, represented by the Gdi1 KO animals. To further test this hypoth-
esis,Gdi1KOandWTanimalswere treatedwith 2-DG. This treatmentwas
able to reverse theworkingmemory defect inGdi1KOmice by competing
with high D-glucose entry but also associative memory, probably acting
on neuronal activity. Moreover, the results that working, but not associa-
tive short-term,memory formationwas affected by astrocyticαGDI abla-
tion in postnatal life is consistent with the view that astrocytes act as
signal integrators due to their very slow stimulus-vesicle secretion cou-
pling [52,53].
The electrophysiological data indicate that the frequency of sponta-
neous glutamatergic ESPCs in cortical neurons was reduced in Gdi1 KO
mice as compared to WT, suggesting a decrease in presynaptic gluta-
mate release. Such effect is consistent with the cognitive deficits we ob-
served in Gdi1 KO mice (Fig. 5). We also detected an increase in the
average sEPSC amplitude in Gdi1 KOmice, perhaps due to a compensa-
tory effect against reduced frequency. SinceαGDI is involved in control-
ling vesicle trafficking, we cannot exclude a direct negative impact on
vesicle release in slices from Gdi1 KOmice. However, 2-DG significantly
restored the diminished frequency of sEPSC inGdi1KOmice, confirming
that this deficit is caused, at least in part, by facilitated glycolysis and D-
glucose utilization. Interestingly, extracellular perfusion with 2-DG
exerted no significant effects on sEPSCs in WT slices, consistent with a
recent report [54]. Moreover, increased D-glucose utilization may result
in excessive local L-lactate availability for synapses. Recent data re-
ported that lactate attenuates glutamatergic synaptic transmission and14perturbs network oscillations in gamma and theta-gamma frequency
ranges in hippocampal slices [55], again supporting the view that syn-
aptic and cognitive deficits in our model are caused by metabolic
dysfunctions.
In summary, the results in this study revealed that in theGdi1mouse
XLID model, the utilization of D-glucose by astrocytes is facilitated. The
nature of this change arises from the mutation of Gdi1 causing a pleio-
tropic deregulation primarily of vesicle traffic [47], and secondarily al-
tering the cell surface signalling landscape regulating aerobic
glycolysis in astrocytes. Thiswas demonstrated by slightly increased ad-
renergic receptors at the plasmamembrane and by the increased sensi-
tivity of cAMP signalling to relatively low levels of extracellular L-lactate,
which activates a yet unknown L-lactate receptor. Moreover, based on
immunocytochemistry ofMCT1 andMCT4 andmeasurements of the in-
tracellular concentration of L-lactate, the transport of L-lactate across the
plasma membrane appears unchanged. However, the NA- and 3Cl-5-
OH-BA-induced increase in [glucose]i appears changed, indicating a
more efficient utilization of D-glucose in aerobic glycolysis in Gdi1 KO
astrocytes. In support of this, administration of 2-DG, which can enter
cells, but cannot be metabolized to generate L-lactate, reverses working
memory impairment in Gdi1 KO mice. Thus, astrocyte-based glycolytic
mechanisms may represent a novel target strategy to treat intellectual
disability. Moreover, our data are consistent with a previous report
showing that metabolic reprogramming in astrocytes is present in a
Huntington mice model [56], however, whether the changes in D-
glucose utilization observed in our study affect also mitochondrial me-
tabolism, needs to be further studied.
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